U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07134335) titled 'UBT251 Injection Phase II Clinical Study (CKD)' on Aug. 13.
Brief Summary: This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
Study Start Date: July 11
Study Type: INTERVENTIONAL
Condition:
Obesity &Amp; Overweight
Chronic Kidney Disease
Intervention:
DRUG: UBT251
Subcutaneous injection once weekly
DRUG: UBT251
Subcutaneous injection once weekly
DRUG: UBT251
Subcutaneous injection once weekly
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: The United Bio-Technology (H...